MediPoint: Predictive Breast Cancer Gene Testing - Current and Future Players



Summary



Breast cancer is the most common form of cancer in women in both the developed and developing world. The incidence of breast cancer is increasing due to the increased life span and increasing adoption of Western lifestyle risk factors. Improved surveillance in developing countries has allowed the identification of more women with breast cancer in these regions. Early diagnosis of breast cancer is essential for a good prognosis, making diagnosis a cornerstone of breast cancer control. Predictive gene testing can identify women who are at heightened risk of developing breast cancer due to hereditary gene factors. This report focuses on the predictive breast cancer gene testing markets in the US and Europe, and future markets in China, India and Brazil, identifying and competitively assessing current marketed and pipeline products and emerging technologies.

This report identifies the unmet needs in the market, provides an understanding of physician perception of predictive breast cancer gene testing, and future trends. Through GlobalData’s analysis, it is evident that the predictive breast cancer gene testing market is dominated by a single player, but this may change in the near future thanks to expiry of key patents and the emergence of new DNA sequencing technologies. To successfully market new gene tests, companies need to offer gene tests that address the current unmet needs of current predictive breast cancer gene tests and show better efficacy and cost effectiveness to the gene tests currently in the market. This report will identify the opportunities for this technology.



Scope


- Investigation of current and future market competition for predictive breast cancer gene testing.
- Competitor assessment.
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the device sector through market impact analysis, future market scenario and company analysis.
- Direct quotes from Key Opinion Leaders (KOL) as well as oncologists, geneticists and genetic counselors already using these gene tests.



Reasons to buy


- Gain a high level view of the trends shaping and driving the predictive breast cancer gene testing market.
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape
- Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market

Table Of Contents

Table of Contents

1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
3 Competitive Assessment 9
3.1 Overview 9
3.1.1 BRACAnalysis 10
3.1.2 BreastNext 18
3.1.3 BreastCancer 24
3.1.4 PreventionGenetics CHEK2/BARD1 Sequencing 26
3.1.5 NewGene NGS BRCA1/2 29
3.1.6 TDL BRCA1/2 Full Screening 31
3.1.7 Centogene Breast Ovarian Cancer NGS Panel 33
3.1.8 Mamma GeneProfile 36
3.1.9 23AndMe DNA Spit Kit 38
3.1.10 DeCodeMe Complete Scan 44
3.1.11 Health Compass 46
4 Pipeline Products 48
4.1 Predictive Breast Cancer Gene Tests in Development 48
4.1.1 Myriad Genetics RAD51C Breast Cancer Gene Test 49
4.1.2 23AndMe Exome 80X 50
4.2 Breast Cancer Gene Expression Tests 50
4.2.1 BreastGeneDX 51
4.2.2 Diagnostic Test - Breast Cancer (Queens University/Almac Diagnostics) 52
4.2.3 Diagnostic Test - Breast Cancer (NanoIVD) 53
4.2.4 EpiSwitch OBD27 54
4.2.5 Myriad HRD Test 55
4.2.6 PAM50 Breast Cancer Test 56
4.3 Emerging Sequencing Technology 57
4.4 New Gene Discovery 57
5 Current and Future Players 58
5.1 Overview 58
5.2 Trends in Corporate Strategy 59
5.3 Common Strengths, Weaknesses, Opportunities and Threats 60
5.3.1 Growing Incidence of Breast Cancer 60
5.3.2 Growing Market Opportunities in Emerging Markets 61
5.3.3 Uncertain RandD Outcomes 62
5.3.4 Stringent Government Regulations 62
5.4 Company Profiles 63
5.4.1 Myriad Genetics 63
5.4.2 Ambry Genetics 74
5.4.3 Complete Genomics 78
5.4.4 Navigenics (now Life Technologies) 83
5.4.5 PreventionGenetics 87
5.4.6 Lab21 Ltd. 89
5.4.7 NewGene Ltd. 93
5.4.8 The Doctors Laboratory Ltd. 96
5.4.9 Bioscientia GmBH 99
5.4.10 Centogene AG (Centogene Rostock GmBH) 101
5.4.11 Sistemas Genomicos 103
5.4.12 Grupo Fleury 106
5.4.13 Diagnosticos da America SA (DASA) 109
5.4.14 ATS GeneTech 112
5.4.15 23AndMe 116
5.4.16 BGI-Shenzhen 125
5.4.17 Illumina 129
5.4.18 Life Technologies 137
5.4.19 Roche 143
6 Appendix 147
6.1 Bibliography 147
6.2 Abbreviations 162
6.3 Research Methodology 164
6.3.1 Overview 164
6.3.2 Coverage 164
6.3.3 Secondary Research 165
6.3.4 Forecast Methodology 165
6.4 Physicians and Specialists Included in this Study 167
6.5 Primary Research 168
6.6 Physician Survey 168
6.7 About the Authors 169
6.7.1 Analysts 169
6.7.2 Global Head of Healthcare 170
6.8 Definitions 171
6.9 About MediPoint 172
6.10 About GlobalData 172
6.11 Contact Us 172
6.12 Disclaimer 173



List of Tables

Table 1: BRACAnalysis Product Profile 10
Table 2: BRACAnalysis SWOT Analysis 17
Table 3: BreastNext Product Profile 18
Table 4: BreastNext SWOT Analysis 24
Table 5: BreastCancer Product Profile 24
Table 6: BreastCancer SWOT Analysis 26
Table 7: PreventionGenetics Product Profile 26
Table 8: PreventionGenetics SWOT Analysis 28
Table 9: NewGene NGS BRCA Product Profile 29
Table 10: NewGene NGS BRCA SWOT Analysis 30
Table 11: TDL BRCA Full Screen Product Profile 31
Table 12: TDL BRCA Full Screen SWOT Analysis 33
Table 13: Centogene Breast Ovarian Cancer NGS Panel Product Profile 33
Table 14: Centogene Breast Ovarian Cancer NGS Panel SWOT Analysis 35
Table 15: Mamma GeneProfile Product Profile 36
Table 16: Mamma GeneProfile SWOT Analysis 38
Table 17: 23AndMe Spit Kit Product Profile 38
Table 18: 23AndMe Spit Kit SWOT Analysis 43
Table 19: Complete Scan Product Profile 44
Table 20: Complete Scan SWOT Analysis 46
Table 21: Health Compass Product Profile 46
Table 22: Health Compass SWOT Analysis 47
Table 23: Predictive Breast Cancer Gene Test Product Pipeline 48
Table 24: Myriad Genetics RAD51C Breast Cancer Gene Test SWOT Analysis 49
Table 25: 23AndMe Exome 80X SWOT Analysis 50
Table 26: Breast Cancer Gene Expression Product Pipeline 50
Table 27: BreastDX SWOT Analysis 51
Table 28: Diagnostic Test - Breast Cancer (Queens University/Almac Diagnostics) SWOT Analysis 52
Table 29: NanoIVD Diagnostic Test - Breast Cancer SWOT Analysis 53
Table 30: EpiSwitch OBD27 SWOT Analysis 54
Table 31: Myriad HRD Test SWOT Analysis 55
Table 32: NanoString PAM50 Breast Cancer Test SWOT Analysis 56
Table 33: Myriad Genetics SWOT Analysis 63
Table 34: Myriad Genetics Product Portfolio 64
Table 35: Myriad Genetics BRACAnalysis Key Patents 68
Table 36: Ambry Genetics SWOT Analysis 74
Table 37: Complete Genomics SWOT Analysis 78
Table 38: Navigenics SWOT Analysis 83
Table 39: PreventionGenetics SWOT Analysis 87
Table 40: Lab21 SWOT Analysis 89
Table 41: Sample Prices for NHS Gene Tests (November 2012) 92
Table 42: NewGene SWOT Analysis 93
Table 43: TDL SWOT Analysis 96
Table 44: Bioscientia SWOT Analysis 99
Table 45: Centogene SWOT Analysis 101
Table 46: Sistemas Genomicos SWOT Analysis 103
Table 47: Grupo Fleury SWOT Analysis 106
Table 48: DASA SWOT Analysis 109
Table 49: ATS GeneTech SWOT Analysis 112
Table 50: BRCA Breast Cancer Scientific Publications and Breast Cancer Incidence 115
Table 51: 23AndMe SWOT Analysis 116
Table 52: BGI-Shenzhen SWOT Analysis 125
Table 53: Illumina SWOT Analysis 129
Table 54: Life Technologies SWOT Analysis 137
Table 55: Roche SWOT Analysis 143
Table 56: Physicians Surveyed, By Country 168



List of Figures

Figure 1: BRACAnalysis Product Family (2012) 11
Figure 2: BRACAnalysis, Number of Tests, 1997-2012 15
Figure 3: BreastNext Mutation Detection Frequency 20
Figure 4: Average Selling Price of Breast Cancer Gene Tests (November 2012) 23
Figure 5: Growth in 23AndMe Gene Testing, 2007-2012 42
Figure 6: Myriad Genetics Revenue and Profit, 2005-2012 65
Figure 7: BRCA Gene Testing by the UK Genetics Testing Network in 2010 71
Figure 8: Visual Representation of Hereditary Breast Cancer Genes (Ambry Genetics) 76
Figure 9: Fleury Revenue and Profitability, 2006-2011 107
Figure 10: DASA Financial Performance, 2005-2011 110
Figure 11: Gene Test Provider Brand Recognition in India, n=7 113
Figure 12: Estimated growth in 23AndMe Revenue, 2007-2012 117
Figure 13: Illumina Revenue and Profit, 2005-2011 133
Figure 14: Life Technologies Revenue and Profit, 2007-2011 139
Figure 15: Roche Revenue and Profit, 2005-2011 144



Companies Mentioned

Myriad Genetics
Ambry Genetics
Complete Genomics
Navigenics (now Life Technologies)
PreventionGenetics
Lab21 Ltd.
NewGene Ltd.
The Doctors Laboratory Ltd.
Bioscientia GmBH
Centogene AG (Centogene Rostock G
Sistemas Genomicos
Grupo Fleury
Diagnosticos da A

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

4 Companies

Company Profiles

Cipla Ltd.

India

Cision AB

Sweden

WebMD Health Corp.

United States

CytRx Corp.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.